SCHEMBL13997549

SCHEMBL13997549

Cc1ccc(C(c2ccc(C)c(NC(=O)c3cc(Cl)ccc3O)c2)(C(F)(F)F)C(F)(F)F)cc1C

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TMPRSS4 Q9NRS4 12/20 0.62
P2RX1 P51575 6/20 0.55
P2RX4 Q99571 3/20 0.55
P2RX7 Q99572 3/20 0.55
KCNMA1 Q12791 3/20 0.53
KDM4E B2RXH2 1/20 0.53
NPC1 O15118 1/20 0.53
LMNA P02545 1/20 0.53
POLB P06746 1/20 0.53
MAPT P10636 1/20 0.53
NPY1R P25929 1/20 0.53
HTT P42858 1/20 0.53
NPY2R P49146 1/20 0.53
RAB9A P51151 1/20 0.53
NPSR1 Q6W5P4 1/20 0.53
MEN1 O00255 1/20 0.52
IKBKB O14920 1/20 0.52
CHUK O15111 1/20 0.52
KDR P35968 1/20 0.52
FLT3 P36888 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL330394 0.88 TMPRSS4 (0.79) TMPRSS4P2RX1P2RX4P2RX7KCNMA1
SCHEMBL14112963 0.79 TMPRSS4 (0.64) TMPRSS4P2RX1P2RX4P2RX7KCNMA1
SCHEMBL13213988 0.78 KMT2A (0.52) NPC1LMNAMAPTHTTRAB9A
SCHEMBL330166 0.77 TMPRSS4 (1.00) TMPRSS4P2RX1P2RX4P2RX7KCNMA1
SCHEMBL330184 0.76 TMPRSS4 (0.66) TMPRSS4P2RX1P2RX4P2RX7KCNMA1
SCHEMBL330023 0.76 TMPRSS4 (0.83) TMPRSS4P2RX1P2RX4P2RX7KCNMA1
SCHEMBL14198848 0.76 P2RX1 (0.71) TMPRSS4P2RX1P2RX4P2RX7MEN1
SCHEMBL13955823 0.75 KMT2A (0.50) KCNMA1KDM4ENPC1LMNAPOLB
SCHEMBL13189705 0.75 P2RX1 (0.64) TMPRSS4P2RX1P2RX4P2RX7KCNMA1
SCHEMBL13772243 0.75 KCNMA1 (0.59) TMPRSS4P2RX1P2RX4P2RX7KCNMA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080311074-A1 Inhibitors against activation of NF-kappaB INSTITUTE OF MEDICAL MOLECULAR DESIGN INC. (JP) 2008-12-18 US disclosed
US-20080311074-A1 Inhibitors against activation of NF-kappaB INSTITUTE OF MEDICAL MOLECULAR DESIGN INC. (JP) 2008-12-18 US disclosed
US-20080234233-A1 MEDICAMENT FOR TREATMENT OF NEURODEGENERATIVE DISEASES INSTITUTE OF MEDICINAL MOLECULAR DESIGN INC. (JP) 2008-09-25 US disclosed
US-20080234233-A1 MEDICAMENT FOR TREATMENT OF NEURODEGENERATIVE DISEASES INSTITUTE OF MEDICINAL MOLECULAR DESIGN INC. (JP) 2008-09-25 US disclosed
US-20080090779-A1 ANTIALLERGIC AGENTS INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2008-04-17 US disclosed
US-20080090779-A1 ANTIALLERGIC AGENTS INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2008-04-17 US disclosed
US-20070185059-A1 Antiallergic agents INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2007-08-09 US disclosed
US-20070185059-A1 Antiallergic agents INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2007-08-09 US disclosed
US-20070185110-A1 Antiallergic agents INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2007-08-09 US disclosed
US-20070185110-A1 Antiallergic agents INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2007-08-09 US disclosed
US-20070042997-A1 Medicament for treatment of dermal pigmentation INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2007-02-22 US disclosed
US-20070042997-A1 Medicament for treatment of dermal pigmentation INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2007-02-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080311074-A1 Inhibitors against activation of NF-kappaB NFKBIA, IKBKB, RELA TMPRSS4 2764/4885P2RX1 4560/4885P2RX4 4767/4885
US-20080090779-A1 ANTIALLERGIC AGENTS NAT1, EPX, HRH2 TMPRSS4 4322/4885P2RX1 2484/4885P2RX4 3324/4885
US-20080234233-A1 MEDICAMENT FOR TREATMENT OF NEURODEGENERATIVE DISEASES MAPT, TFEB, MAOA TMPRSS4 4257/4885P2RX1 4680/4885P2RX4 4774/4885
US-20070185110-A1 Antiallergic agents NAT1, EPX, AHR TMPRSS4 4402/4885P2RX1 2425/4885P2RX4 3298/4885
US-20070185059-A1 Antiallergic agents NAT1, EPX, AHR TMPRSS4 4368/4885P2RX1 2389/4885P2RX4 3242/4885
US-20070042997-A1 Medicament for treatment of dermal pigmentation TYR, XDH, XPA TMPRSS4 4665/4885P2RX1 4040/4885P2RX4 4374/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.